KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to 0.77.

  • Regeneron Pharmaceuticals' Equity Ratio fell 86.53% to 0.77 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.77, marking a year-over-year decrease of 86.53%. This contributed to the annual value of 0.77 for FY2025, which is 86.53% down from last year.
  • Regeneron Pharmaceuticals' Equity Ratio amounted to 0.77 in Q4 2025, which was down 86.53% from 0.77 recorded in Q3 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Equity Ratio peaked at 0.79 during Q1 2024, and registered a low of 0.67 during Q1 2021.
  • In the last 5 years, Regeneron Pharmaceuticals' Equity Ratio had a median value of 0.78 in 2022 and averaged 0.76.
  • The largest annual percentage gain for Regeneron Pharmaceuticals' Equity Ratio in the last 5 years was 1580.9% (2021), contrasted with its biggest fall of 1247.62% (2021).
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Equity Ratio stood at 0.74 in 2021, then grew by 5.13% to 0.78 in 2022, then increased by 1.21% to 0.79 in 2023, then decreased by 0.99% to 0.78 in 2024, then decreased by 0.87% to 0.77 in 2025.
  • Its Equity Ratio was 0.77 in Q4 2025, compared to 0.77 in Q3 2025 and 0.78 in Q2 2025.